An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05146882 |
|
Recruitment Status :
Withdrawn
(Update to Program Design - No Participants Enrolled)
First Posted : December 7, 2021
Last Update Posted : June 27, 2022
|
Sponsor:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Information provided by (Responsible Party):
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | May 23, 2022 |
| Actual Study Completion Date : | May 23, 2022 |